

FORM PTO-1390 U.S. DEPARTMENT OF COMMERCE PATENT AND TRADEMARK OFFICE (MODIFIED)

ATTORNEY'S DOCKET NUMBER

X-16177

U.S. APPLICATION NO. (if known, see 37 C.F.R. 1.5)

10/575469

**TRANSMITTAL LETTER TO THE UNITED STATES
DESIGNATED/ELECTED OFFICE (DO/EO/US)
CONCERNING A FILING UNDER 35 U.S.C. 371**

INTERNATIONAL APPLICATION NO.
PCT/US2004/038240

INTERNATIONAL FILING DATE
10 December 2004 (10.12.2004)

PRIORITY DATE CLAIMED
23 December 2003 (23.12.2003)

TITLE OF INVENTION: MORPHOLINE DERIVATIVES AS NOREPINEPHRINE REUPTAKE INHIBITORS

APPLICANT(S) FOR DO/EO/US: Peter Thaddeus GALLAGHER, Carlos LAMAS-PETEIRA, and Francisco Javier AGEJAS-CHICHARRO

Applicant herewith submits to the U.S. Designated/Elected Office (DO/EO/US) the following items and other information:

1. This is a **FIRST** submission of items concerning a filing under 35 U.S.C. 371.
2. This is a **SECOND** or **SUBSEQUENT** submission of items concerning a filing under 35 U.S.C. 371.
3. This express request to begin national examination procedures (35 U.S.C. 371(f)) at any time rather than delay examination until the expiration of the applicable time limit set in 35 U.S.C. 371(b) and PCT Articles 22 and 39(1).
4. The US has been elected (Article 31).
5. A copy of the International Application as filed (35 U.S.C. 371(c)(2))
 - a. is transmitted herewith (required only if not transmitted by the International Bureau).
 - b. has been transmitted by the International Bureau.
 - c. is not required, as the application was filed in the United States Receiving Office (RO/US).
6. A translation of the International Application into English (35 U.S.C. 371(c)(2)).
7. Amendments to the claims of the International Application under PCT Article 19 (35 U.S.C. 371(c)(3))
 - a. are transmitted herewith (required only if not transmitted by the International Bureau).
 - b. have been transmitted by the International Bureau.
 - c. have not been made; however, the time limit for making such amendments has NOT expired.
 - d. have not been made and will not be made.
8. A translation of the amendments to the claims under PCT Article 19 (35 U.S.C. 371(c)(3)).
9. An oath or declaration of the inventor(s) (35 U.S.C. 371(c)(4)).
10. A declaration of the inventors 35 U.S.C. 371(c)(4) was provided in the PCT Request Form.
11. A copy of the International Preliminary Examination Report (IPER), including any annexes, and, if not in English, an English language translation of the annexes to the IPER under PCT Article 36 (35 U.S.C. 371(c)(5)).

Items 12. to 18. below concern document(s) or information included:

12. An Information Disclosure Statement under 37 CFR 1.97 and 1.98. Search Report/Written Opinion (ISA/EP)
13. An assignment document for recording. A separate cover sheet in compliance with 37 CFR 3.28 and 3.31 is included.
14. Assignment has been recorded at reel _____, frame _____.
15. A FIRST preliminary amendment.
16. A SECOND or SUBSEQUENT preliminary amendment.
17. A Sequence Listing, 1.821 Statement, and diskette.
18. A change of power of attorney with attachment.
18. Other items or information:

Please amend the first page of the specification by inserting the following cross-reference after the title:

"This is the national phase application, under 35 USC 371, for PCT/US2004/038240, filed 10 December 2004, which claims the benefit of EP 03380306.5, filed 23 December 2003, and US provisional application 60/547,519, filed 25 February 2004."

U.S. APPLICATION NO. (if known) 37 C.F.R. 1.5) 107575469		INTERNATIONAL APPLICATION NO. PCT/US2004/038240	ATTORNEY'S DOCKET NUMBER X-16177
19.	<input checked="" type="checkbox"/> The following fees are submitted:	CALCULATIONS PTO USE ONLY	
(a)	Basic national fee (37 CFR 1.492(a)).....	\$300.00	
(b)	Examination fee (37 CFR 1.492(c)) If the written opinion prepared by ISA/US or the international preliminary examination report prepared by IPEA/US indicates all claims satisfy provisions of PCT Article 33(1)-(4).....\$0 All other situations.....\$200	\$200.00	
(c)	Search fee (37 CFR 1.492(b)) If the written opinion of the ISA/US or the International preliminary examination report prepared by IPEA/US indicates all claims satisfy provisions of PCT Article 33(1)-(4).....\$0 Search fee (37 CFR 1.445(a)(2)) has been paid on the international application to the USPTO as an International Searching Authority.....\$100 International Search Report prepared by an ISA other than the US and provided to the Office or previously communicated to the US by the IB.....\$400 All other situations.....\$500	\$400.00	
TOTAL AMOUNT (a + b + c) =		\$ 900.00	
Surcharge of \$130.00 for furnishing the oath or declaration later than 30 months from the earliest claimed priority date (37 CFR 1.492(e)).		\$	
CLAIMS		NUMBER FILED	NUMBER EXTRA
Total claims		11 -20=	0
Independent claims		1 -3=	0
MULTIPLE DEPENDENT CLAIM(S) (if applicable)		+ \$360.00	
TOTAL OF ABOVE CALCULATIONS =		\$	
Reduction by 1/2 for filing by small entity, if applicable. Verified Small Entity Statement must also be filed (Note 37 CFR 1.9, 1.27, 1.28).		\$	
		SUBTOTAL = \$ 900.00	
Processing fee of \$130.00 for furnishing English translation later than 30 months from the earliest claimed priority date (37 CFR 1.492(f)).		+\$	
		TOTAL NATIONAL FEE = \$ 900.00	
Fee for recording the enclosed assignment (37 CFR 1.21(h)). The assignment must be accompanied by an appropriate cover sheet (37 CFR 3.28, 3.31).		\$	
		\$40.00 per property +	
		TOTAL FEES ENCLOSED = \$ 900.00	
		Amount to be refunded	\$
		charged	\$
a.	<input type="checkbox"/>	A check in the amount of \$_____ to cover the above fees is enclosed.	
b.	<input checked="" type="checkbox"/>	Please charge my Deposit Account No. 05-0840 in the amount of <u>\$900.00</u> to cover the above fees. A duplicate copy of this sheet is enclosed.	
c.	<input checked="" type="checkbox"/>	The Commissioner is hereby authorized to charge any additional fees which may be required, or credit any overpayment to Deposit Account No. 05-0840. A duplicate copy of this sheet is enclosed.	
NOTE: Where an appropriate time limit under 37 CFR 1.494 or 1.495 has not been met, a petition to revive (37 CFR 1.137(a) or (b)) must be filed and granted to restore the application to pending status.			
SEND ALL CORRESPONDENCE TO: ELI LILLY AND COMPANY PATENT DIVISION P.O. BOX 6288 INDIANAPOLIS, INDIANA 46206-6288 <i>12 April 2006</i>		<i>Charles E. Cohen</i> SIGNATURE Charles E. Cohen	 25885 PATENT TRADEMARK OFFICE
DATE 34,565		TELEPHONE NUMBER 317-433-4983	
REGISTRATION NUMBER			

10/575469

IAP9 Rec'd PCT/PTO 12 APR 2006

IN THE UNITED STATES RECEIVING OFFICE (USRO)

Applicants: Peter Thaddeus GALLAGHER
Carlos LAMAS-PETEIRA
Francisco Javier AGEJAS-CHICHARRO

International Application No.: PCT/US2004/038240

Filed: 10 December 2004 (10.12.2004)

Invention: MORPHOLINE DERIVATIVES AS NOREPINEPHRINE REUPTAKE INHIBITORS

Lilly Reference: X-16177

Earliest Priority Date: 23 December 2003 (23.12.2003)

Certificate Under 37 C.F.R. § 1.10

Attention: DO/EO
Mail Stop PCT
Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450

Sir/Madam:

"Express Mail" mailing label number: EV 393129155 US

Date of Deposit: Apr. 12, 2006

I hereby certify that the following attached paper or fee

Transmittal Letter to the United States Designated/Elected Office (US) concerning a filing under 35 U.S.C. 371 of the International Application identified above is being deposited with the United States Postal Service "Express Mail Post Office to Addressee" service under 37 C.F.R. 1.10 on the date indicated above and is addressed to the Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

Queena Thomas
(Typed or printed name of person mailing paper)

Queena Thomas
(Signature of person mailing paper or fee)